A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus

Author:

Shang Zhenhai¹²,Han Feifei¹³,Zhou Xueyan¹^ORCID,Bao Zejun¹,Zhu Jing⁴,Wang Tao²,Lu Qian¹,Du Lei¹,Li Wei⁵,Lv Dongmei²,Yin Xiaoxing¹^ORCID

Affiliation:

1. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy; Xuzhou Medical University; Xuzhou China

2. Department of Pharmacy; the Affiliated Hospital of Xuzhou Medical University; Xuzhou China

3. Department of Diagnostics; Clinical College, Xuzhou Medical University; Xuzhou China

4. Department of Pharmacy; the First Affiliated Hospital of Soochow University; Suzhou China

5. Department of Endocrinology; the Affiliated Hospital of Xuzhou Medical University; Xuzhou China

Funder

Open Research Fund of Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy

Publisher

Wiley

Subject

Drug Discovery

Reference40 articles.

3. Pharmacogenomics of glinides;Chen;Pharmacogenomics,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献